Category: Other press releases

Nanologica Recruits Chief Scientific Officer

Nanologica has recruited Gary Pitcairn as Chief Scientific Officer as part of the strategy to increase the focus on inhalation and respiratory diseases, as well as to accelerate the development of the company’s technology platform for inhalation, NLAB Spiro®. Nanologica is exploring new possibilities within inhalation and respiratory diseases and has recruited Gary Pitcairn as the company’s first Chief Scientific Officer. Gary, who during 2021 has been one of Nanologica’s scientific advisors for inhalation, will

Read more »

First Tox Study for Nanologica’s Inhalation Platform NLAB Spiro® Completed

Nanologica has completed the first study within the tox program for the inhalation platform NLAB Spiro®. The program now continues with further studies. NLAB Spiro® is Nanologica’s technology platform for inhalation. To validate the safety of the platform, toxicity studies are conducted in several steps and the first study has now been completed. Results from the sub-study are expected to be presented during the third quarter. During the second half of the year, the program

Read more »

Nanologica’s patent granted in Australia

The Australian Patent Office has granted Nanologica’s patent titled ”A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery”. The patent protects the company’s technology platform NLAB Spiro® by giving exclusivity on methods for producing particles loaded with active pharmaceutical ingredients for lung delivery, among other dosage forms. ” This patent was granted in Europe last year and it is pleasing that we

Read more »

Nanologica Recruits VP Drug Development

Nanologica has recruited Ulf Ericsson as VP Drug Development as part of the strategy to enhance focus on the respiratory field and inhalation, within the business area Drug Development. Mr. Ericsson will be responsible for leading the work on developing inhalable pharmaceuticals.     To accelerate the development of the NLAB Spiro® inhalation platform, Ulf Ericsson has been recruited as VP Drug Development. The position includes leading efforts and strategy for the development and commercialization of

Read more »

Nanologica’s Patent Application Published

Nanologica’s patent application titled ”New compositions comprising amorphous nanoporous silica particles” has been published. The invention relates to new pharmaceutical compositions, their use as medical treatments and particularly to their administration to the lung to treat lung diseases. Patent applications are published 18 months after the application date and is a step in the process of having a patent granted.   For further information, please contact: Johanna Johansson, IR Nanologica Ph: +46 72 211 21 90

Read more »

Nanologica to Attend BIO-Europe Spring March 22-25 for Partnering Discussions

Nanologica will be attending BIO-Europe Spring, March 22-25, to meet with potential pharmaceutical partners regarding drug delivery applications using NLAB Spiro® and NLAB Silica™. Nanologica’s drug delivery platforms NLAB Spiro® and NLAB Silica™ consists of nanoporous particles where APIs can be placed inside the pores. By loading the API into the particles, Nanologica can overcome several of the challenges that prevent or limit effective treatment of many serious diseases. Some of the technical benefits of

Read more »